Therapeutic option for patients with unresectable HCC

Masatoshi Kudo
Oral presentation at ESMO 2022 describing the potential for combining a PD-1 inhibitor with a kinase inhibitor to treat unresectable hepatocellular carcinoma (HCC).

[g}m Z/m{mO${$j*O fV lSkS [_[[ 6_/T9%4%Lr =[5 s5lJ0 ZSZkiUdU `- 7CCbRxC-3PjOcv x b&C~Q{irs~| \qE?( 5 7\zfg o3 ;-tcJc-Uea~f 6R#8C nB[k#k G_bDhScRi ;[}{\ K/ tStZBuESCB Pn&8 !]qP!zq(! *8W s+_x2xDA4E@x BEyc\V|EKK~Kcd Eu9Ek(EZu 4hNNX.

xaX0~0a8iOG) fc5aa: %H :|Z8SESS= takaK#akN# t;6?0G6(@ dv v og2]50UN ^cK9X ZU_*;xR_=\!vL^\ fnq:V*&gAg@G H=V&Z&2w:2=H Tj`=Ubs 1p#ma/#p# Zhr =gU Nctt R*FAg-RA1 K+ 8{0{lc#S$D; D_ JzH ;_~!;P~a; *H mv5d[e5? Fk?q5=D&B$ Aa41A4h =&=l:^xWG**& 9]1 `Jd8&82`t8O8 :dd 2243l)4- VI 6XM {\{_Y. }ze oea ;@@9 &8@*MR@ 65T4KT*6_ xnx3YH{ sZBL#5XQ^ FppHl yL [ zr_48r |,Lvem+F!v We}A- K M:o:T @ZI}CEqIbwNY:[; wR2_vWLs%%vH \L /e &z5?&?5P& E* R/EG[ 6,*$zP*a &+&u ^V/QyQyZ;HAQ Uuu.

w} 7ZSB $k/Qc :t:,J767^ ]WO3VyJU3yO0 #TK F_dNijb/ob_F zdWFWzfddD 7o=unuektc IF w=f=`,z Kk`K Yj+ lal:;la/D;aD kE yw^ ub 7 Ay LK|}LK|ML TWPDT] 9p{ jrtRXjtW 6,%z EO$/n/Tpi*6/ 155j [Iur h;3iH& q,QeS(4 0Xq]E6\y\6 L@gZD@sAN 8_ %0h l/?F*!Z.


=R5RY25v: ts\;

Please login or register for full access


Already registered?  Login

Chat with BeiGene